The take outs in biotech continues
Sanofi acquires Arctic Aurora LifeScience portfolio company Blueprint Medicines
On 2 June 2025, the French pharmaceutical company announced its agreement to acquire the Boston-based biotech company Blueprint Medicines in a deal valued at 9.5 billion USD. The acquisition centres on Blueprint's flagship drug, Ayvakit (avapritinib), which is the only approved treatment for advanced systemic mastocytosis in both the EU and the US. Ayvakit generated USD 150 million in sales in the first quarter of 2025, with projected peak annual sales of around USD 2 billion. Systemic mastocytosis is an immunological disease involving the overactivation of mast cells, which build up in the organs and cause severe allergy-like symptoms. In severe cases, the disease can damage the organs.
Beyond the Ayvakit drug, Sanofi will gain access to Blueprint’s immunology pipeline, which includes several compounds focused on immunology. Among these is a Phase III asset that is also aimed at different types of mastocytosis.
This acquisition will add important diversification to Sanofi’s product portfolio, reducing its reliance on its blockbuster eczema drug Dupixent.
In addition to the cash offer of USD 129 per share, Blueprint shareholders will also receive CVRs (milestone-related extra payments) of up to USD 6 per share. Overall, the deal represents a premium of 33% including the CVRs, or 27% based on the cash payment alone.
Blueprint is one of the companies in the Commercial Biotech segment of the fund. This segment consists of companies with an innovative pipeline that are also mature enough to have a marketed product. This segment is attractive to larger companies as commercial drugs can be easily incorporated into their product portfolios with minimal development risk. As many of these companies have generally been traded down due to market uncertainty and poor biotech sentiment, several of them are currently trading at low valuations. At these levels, industrial buyers recognize value.
Latest news
Arctic Asset Management - Arctic Midt i Måneden - Smooth sailing beneath choppy waters
Teamet har levert sterk aksjeavkastning over tid – i både krevende og skiftende markeder. I denne episoden forteller våre erfarne aksjeforvaltere hvordan de navigerer i en verden preget av støy, skiftende signaler og uro. Sindre Sørbye og Ole Dahl er i studio hos Albert Collett.
Arctic Asset Management - Vera Therapeutics soars on strong Phase 3 results in rare kidney disease
Arctic Aurora LifeScience and Arctic Aurora Biotech Select holding Vera Therapeutics increased more than 65% on June 2, upon announcing competitive phase 3 clinical data in IgAN, a severe kidney disorder.
Arctic Asset Management - Markedskommentar mai 2025
Mai måned viste en sterk utvikling i globale finansmarkeder, preget av økt risikovilje etter turbulensen i april. Verdensindeksen (MSCI World i NOK) steg 5,9 %, mens amerikanske aksjer, representert ved S&P 500 (USD), økte med 6,2 %. Oslo Børs (OSEFX, NOK) hadde også en positiv måned med en oppgang på 5,3 %, drevet av bred sektoroppgang hvor spesielt energi og finans bidro sterkt, mens sektoren defensivt konsum trakk ned, hovedsakelig på grunn av svak utvikling innen lakseoppdrett. Norden (VINX Index, NOK) steg markedet med 2,6 %, hvor industri og finans var de største positive bidragsyterne, mens eiendom bidro negativt.
Arctic Asset Management - Gjeld, usikkerhet og en fisk med potensial
I mai-episoden av Arctic Midt i Måneden ser vi nærmere på USAs økende gjeld og spør om landet har økonomisk styrke til å håndtere renteutgiftene. Vi snakker også om hvorfor "usikkerhet" er blitt et nøkkelord i årets rapporteringssesong, hvordan fondene er posisjonert – og hva som gjør en fisk til et fristende investeringscase. Forvalterne Trond Tømmerås og Alexander Larstedt Lager er gjester i studio hos investeringsdirektør Albert Collett.
Arctic Asset Management - What has caused the recent volatility in the healthcare sector?
Arctic Aurora LifeScience's CIO, Ulrica Slåne Bjerke, and portfolio manager, Daniel Bolanowski, share their thoughts on what caused the sector's bumpy ride in April and the first few days of May.
Arctic Asset Management - Markedskommentar april 2025
Nyhetsbildet i april var preget av sterke utspill fra president Trump der hans ‘Liberation Day’ tariff-annonseringer 2. april skapte ekstreme svingninger i finansmarkedene de påfølgende dagene.